The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...
The tumor suppressor protein p53 plays a critical role in preventing cancer by regulating cell cycle, apoptosis, and genomic stability. However, mutations in the P53 gene are found in over 50% of ...
Compound d16 reduces tumor growth and overcomes therapeutic resistance in mutant p53-bearing cancers
Researchers at Baylor College of Medicine have developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers in the lab. The ...
A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells." Researchers ...
Design of a phase 1 trial of Listeria monocytogenes 11-T856-1313 tetanus toxoid (Lm-LLO-TT) for pancreatic ductal adenocarcinoma (PDAC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 ...
A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results